Chemours Stock Forecast, Price & News

Chemours (NYSE:CC) Frequently Asked Questions

Is Chemours a buy right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Chemours in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Chemours stock.
View analyst ratings for Chemours or view top-rated stocks.

How has Chemours' stock price been impacted by COVID-19 (Coronavirus)?

Chemours' stock was trading at $10.66 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CC stock has increased by 176.6% and is now trading at $29.49.
View which stocks have been most impacted by COVID-19.

When is Chemours' next earnings date?

Chemours is scheduled to release its next quarterly earnings announcement on Thursday, February 10th 2022.
View our earnings forecast for Chemours.

How were Chemours' earnings last quarter?

The Chemours Company (NYSE:CC) announced its quarterly earnings data on Thursday, November, 4th. The specialty chemicals company reported $1.27 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.99 by $0.28. The specialty chemicals company had revenue of $1.68 billion for the quarter, compared to analysts' expectations of $1.58 billion. Chemours had a net margin of 6.51% and a trailing twelve-month return on equity of 72.01%. The company's quarterly revenue was up 36.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.47 earnings per share.
View Chemours' earnings history.

How often does Chemours pay dividends? What is the dividend yield for Chemours?

Chemours declared a quarterly dividend on Wednesday, October 27th. Shareholders of record on Monday, November 15th will be given a dividend of $0.25 per share on Wednesday, December 15th. This represents a $1.00 annualized dividend and a yield of 3.39%. The ex-dividend date is Friday, November 12th.
View Chemours' dividend history.

Is Chemours a good dividend stock?

Chemours pays an annual dividend of $1.00 per share and currently has a dividend yield of 3.24%. The dividend payout ratio of Chemours is 42.74%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Chemours will have a dividend payout ratio of 22.78% next year. This indicates that Chemours will be able to sustain or increase its dividend.
View Chemours' dividend history.

What guidance has Chemours issued on next quarter's earnings?

Chemours issued an update on its FY 2021 earnings guidance on Thursday, November, 25th. The company provided earnings per share guidance of $3.930-$4.130 for the period, compared to the Thomson Reuters consensus estimate of $3.670. The company issued revenue guidance of -.

What price target have analysts set for CC?

9 Wall Street analysts have issued twelve-month price objectives for Chemours' shares. Their forecasts range from $28.00 to $48.00. On average, they anticipate Chemours' share price to reach $38.33 in the next year. This suggests a possible upside of 30.0% from the stock's current price.
View analysts' price targets for Chemours or view top-rated stocks among Wall Street analysts.

Who are Chemours' key executives?

Chemours' management team includes the following people:

• Mark E. Newman, President, CEO, COO, Director & Senior VP
• Sameer Ralhan, Chief Financial Officer & Senior Vice President
• Randal King, VP-Technology & Advanced Performance Materials
• David C. Shelton, Secretary, Senior Vice President & General Counsel
• Camela T. Wisel, Chief Accounting Officer, VP & Controller

What is Mark Vergnano's approval rating as Chemours' CEO?

106 employees have rated Chemours CEO Mark Vergnano on Glassdoor.com. Mark Vergnano has an approval rating of 85% among Chemours' employees.

Who are some of Chemours' key competitors?

Some companies that are related to Chemours include Asahi Kasei (AHKSY), FMC (FMC), Olin (OLN), Huntsman (HUN), Ashland Global (ASH), Johnson Matthey (JMPLY), Balchem (BCPC), Livent (LTHM), Univar Solutions (UNVR), Showa Denko K.K. (SHWDY), Kuraray (KURRY), Ingevity (NGVT), Innospec (IOSP), GCP Applied Technologies (GCP) and SL Industries (SLI).
View all of CC's competitors.

What other stocks do shareholders of Chemours own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Chemours investors own include AT&T (T), Pfizer (PFE), DuPont de Nemours (DD), NVIDIA (NVDA), Cisco Systems (CSCO), Micron Technology (MU), Intel (INTC), AbbVie (ABBV), CVS Health (CVS) and Energy Transfer (ET).

What is Chemours' stock symbol?

Chemours trades on the New York Stock Exchange (NYSE) under the ticker symbol "CC."

Who are Chemours' major shareholders?

Chemours' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.43%), LSV Asset Management (2.27%), Vaughan Nelson Investment Management L.P. (1.34%), Geode Capital Management LLC (1.35%), Bank of New York Mellon Corp (1.34%) and Dimensional Fund Advisors LP (1.27%). Company insiders that own Chemours stock include Alvenia Scarborough, David C Shelton, Denise Dignam, E Bryan Snell, Edwin C Sparks, Mark Newman, Mark P Vergnano, Matthew S Abbott, Richard H Brown and Sameer Ralhan.
View institutional ownership trends for Chemours.

Which major investors are selling Chemours stock?

CC stock was sold by a variety of institutional investors in the last quarter, including Allianz Asset Management GmbH, Invesco Ltd., Two Sigma Advisers LP, Independent Advisor Alliance, Schroder Investment Management Group, LSV Asset Management, Russell Investments Group Ltd., and AXA S.A.. Company insiders that have sold Chemours company stock in the last year include Alvenia Scarborough, David C Shelton, Denise Dignam, Edwin C Sparks, Mark Newman, Mark P Vergnano, Matthew S Abbott, and Sameer Ralhan.
View insider buying and selling activity for Chemours or view top insider-selling stocks.

Which major investors are buying Chemours stock?

CC stock was acquired by a variety of institutional investors in the last quarter, including Luminus Management LLC, Renaissance Technologies LLC, Millennium Management LLC, Balyasny Asset Management LLC, EMG Holdings L.P., American Century Companies Inc., PEAK6 Investments LLC, and Los Angeles Capital Management LLC. Company insiders that have bought Chemours stock in the last two years include E Bryan Snell, Mark Newman, and Richard H Brown.
View insider buying and selling activity for Chemours or or view top insider-buying stocks.

How do I buy shares of Chemours?

Shares of CC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Chemours' stock price today?

One share of CC stock can currently be purchased for approximately $29.49.

How much money does Chemours make?

Chemours has a market capitalization of $4.81 billion and generates $4.97 billion in revenue each year. The specialty chemicals company earns $219 million in net income (profit) each year or $2.34 on an earnings per share basis.

How many employees does Chemours have?

Chemours employs 6,500 workers across the globe.

What is Chemours' official website?

The official website for Chemours is www.chemours.com.

Where are Chemours' headquarters?

Chemours is headquartered at 1007 MARKET STREET, WILMINGTON DE, 19801.

How can I contact Chemours?

Chemours' mailing address is 1007 MARKET STREET, WILMINGTON DE, 19801. The specialty chemicals company can be reached via phone at (302) 773-1000 or via email at [email protected].